| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Raddeanoside R8 has been studied for its potential anti-inflammatory, anticancer, and immunomodulatory activities. Its structural complexity makes it valuable for exploring saponin-related mechanisms. It may target inflammatory pathways and cancer cell signaling.
|
|---|---|
| ln Vitro |
In vitro, Raddeanoside R8 has anti-inflammatory, anticancer, and immunomodulatory activities. It inhibits cancer cell proliferation and modulates immune responses. Detailed in vitro data including IC50 values are limited. It is used in natural product-based therapeutic research.
|
| ln Vivo |
In vivo studies for Raddeanoside R8 are limited. Its anti-inflammatory and anticancer activities suggest potential therapeutic applications. Animal studies are needed to confirm its in vivo efficacy and safety. Traditional use in Chinese medicine supports its potential benefits.
|
| Enzyme Assay |
Cell-free assays for Raddeanoside R8: anti-inflammatory activity is assessed by measuring inhibition of COX-2 or LOX enzyme activities. Anticancer activity is evaluated using cell-free systems such as enzyme inhibition assays (e.g., topoisomerase inhibition). Immunomodulatory activity is assessed by measuring cytokine levels in cell-free systems.
|
| Cell Assay |
Cellular assays for Raddeanoside R8: cancer cell lines and immune cells are cultured and treated with Raddeanoside R8 at concentrations of 0.1-100 µM for 24-72 hours. Cell viability is measured by MTT assay. Apoptosis is assessed by Annexin V/PI staining. Cytokine production is measured by ELISA. Inflammatory markers are assessed by Western blot or qPCR.
|
| Animal Protocol |
In vivo animal studies for Raddeanoside R8: animal models of inflammation and cancer would be used. Animals are administered Raddeanoside R8 orally or intraperitoneally at doses of 10-50 mg/kg. Inflammatory markers, tumor growth, and immune cell function are assessed. Traditional use in Chinese medicine provides a basis for efficacy studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Raddeanoside R8: as a large saponin with molecular weight 1367.53, it may have very poor oral bioavailability. It is likely metabolized by intestinal flora and liver enzymes. Tissue distribution and elimination pathways are not well characterized.
|
| Toxicity/Toxicokinetics |
Toxicity of Raddeanoside R8: comprehensive toxicity data are limited. As a saponin, it may have hemolytic activity and gastrointestinal effects at high doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Raddeanoside R8 is a research compound with potential applications in anti-inflammatory, anticancer, and immunomodulatory research. It is available as a reference standard for pharmacological studies. Its mechanism involves anti-inflammatory and anticancer activities. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C65H106O30
|
|---|---|
| Molecular Weight |
1367.52
|
| Exact Mass |
1366.676
|
| CAS # |
124961-61-1
|
| Appearance |
White to off-white solid
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.641
|
| Source |
Originated from plants: Ranunculaceae Anemone raddeana Regel
Originated from plants: Ranunculaceae Anemone cathayensis Kitag. |
| LogP |
3.86
|
| SMILES |
OC[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC([C@@]34CC[C@]5(C)C(=CC[C@@H]6[C@]7(CC[C@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@@H](O)[C@H](O)[C@@H](CO)O9)[C@@H](O)[C@@H](O)CO8)C(C)(C)[C@@H]7CC[C@]65C)C)[C@@H]3CC(C)(C)CC4)=O)O2)O1
|
| InChi Key |
WZEVPZVUDJNKHG-WJNUHIPTSA-N
|
| InChi Code |
InChI=1S/C65H106O30/c1-25-36(69)41(74)46(79)54(86-25)92-50-31(22-67)89-53(49(82)45(50)78)85-24-32-40(73)43(76)48(81)56(90-32)95-59(83)65-18-16-60(3,4)20-28(65)27-10-11-34-62(7)14-13-35(61(5,6)33(62)12-15-64(34,9)63(27,8)17-19-65)91-57-51(38(71)29(68)23-84-57)94-58-52(44(77)39(72)30(21-66)88-58)93-55-47(80)42(75)37(70)26(2)87-55/h10,25-26,28-58,66-82H,11-24H2,1-9H3/t25-,26-,28-,29-,30+,31+,32+,33-,34+,35-,36-,37-,38-,39+,40+,41+,42+,43-,44-,45+,46+,47+,48+,49+,50+,51+,52+,53+,54-,55-,56-,57-,58-,62-,63+,64+,65-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~36.6 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (0.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (0.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7313 mL | 3.6563 mL | 7.3125 mL | |
| 5 mM | 0.1463 mL | 0.7313 mL | 1.4625 mL | |
| 10 mM | 0.0731 mL | 0.3656 mL | 0.7313 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
